Friberg Gregory R
EVP, Chief R&D Officer
Friberg Gregory R has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: May 11, 2026.
On the most recent filing, Friberg Gregory R is listed as EVP, Chief R&D Officer at BIOMARIN PHARMACEUTICAL INC. Inside the rolling window, Friberg Gregory R reported no open-market purchases and 2 open-market sales totaling $559K in BMRN. The largest disclosed transaction in the window is a sale of 6,326 BMRN shares on Feb 26, 2026, worth $382K.
Companies traded
Other insiders at BMRN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$559K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Friberg Gregory R made?
Friberg Gregory R has filed 4 SEC Form 4 filings (5 transaction rows) across 1 company since 2025.
Which companies does Friberg Gregory R trade?
Friberg Gregory R has filed SEC Form 4 disclosures for 1 company, including BMRN.
When was Friberg Gregory R's most recent SEC Form 4 filing?
Friberg Gregory R's most recent SEC Form 4 filing on Tracefour is dated May 11, 2026.
What is Friberg Gregory R's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Friberg Gregory R is listed as EVP, Chief R&D Officer.
What is Friberg Gregory R's total buy and sell value in the current window?
Inside the rolling retention window, Friberg Gregory R bought $0 and sold $559K based on SEC Form 4 filings.
What was Friberg Gregory R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,326 BMRN shares on 2026-02-26, worth $382K, per SEC Form 4 filings.